Medtronic Changes the Game

Medtronic's eye-popping deal for Covidien is a great move for a company looking to the long-term future of healthcare

Jun 16, 2014 at 11:03AM

In one dramatic swoop, Medtronic (NYSE:MDT) answered a lot of the questions that investors had about its plans for its overseas cash balance, it's long-term growth plans, and whether it wanted to enter additional "power alley" med-tech markets. Medtronic has announced that it will be acquiring Covidien (NYSE:COV) in a cash-and-stock transaction that is not only a tremendously large med-tech deal, but one that makes an exceptional amount of sense.

Medtronic has changed the med-tech game on multiple levels. Not only will the new Medtronic be the most diversified company in med-tech, with leadership in over a half-dozen major therapeutic markets, but the size of this deal may well spur actions to close the tax inversion loopholes that companies have been using to reduce their tax bills. Most importantly of all, it's a good deal for Medtronic and Covidien shareholders, though some will see the tax ramifications as less than ideal.

A big deal in every sense
When rumors started spreading that Medtronic was taking a look at Smith & Nephew, a lot of analysts dismissed them saying that Medtronic wouldn't be interested in a deal of that size. What nobody seemed to think, though, was that Medtronic would consider Smith & Nephew as too small for its ambitions. Instead of buying Smith & Nephew, Medtronic announced a nearly $43 billion deal for Covidien, one of the world leaders in surgery, energy tools, respiratory, and patient monitoring.

Medtronic will be paying $35.19 in cash for each Covidien share and 0.956 shares of the new Medtronic. All told, Covidien shareholders will own 30% of the company and are receiving a 29% premium to Friday's close (though that number will move with Medtronic's stock price). Based upon trailing numbers, the new company will have $27 billion in revenue ($17 billion from Medtronic, $10 billion from Covidien) and $8.7 billion in pre-synergy EBITDA ($5.9 billion from Medtronic).

While there are some overlaps in the two companies' peripheral/endovascular, neurovascular, and energy businesses, most of what Covidien brings to Medtronic is new to the company. Together, this will be the largest player in cardiac rhythm management (pacemakers and ICDs), spinal care, diabetes devices, energy tools, patient monitoring, respiratory care, peripheral vascular, and nursing products, as well as a virtual co-#1 with Johnson & Johnson (NYSE: JNJ) in endomechanical surgical tools.

Can Medtronic reach synergy targets?
When med-techs with large overlapping businesses get together (like in the case of Zimmer and Biomet), there are often revenue dysynergies and sales disruptions. That's much less likely here, given the limited overlap. Over time, Medtronic believes it can see significant cross-selling potential in areas like patient monitoring and adding Covidien's businesses certainly fits with Medtronic's new ideas about integrated health solutions.

A cost synergy goal of $850 million sounds reasonable, with Medtronic looking to drive cost savings from a more efficient manufacturing footprint, more scale in global sourcing, and the elimination of redundant back-office costs. Given the lack of overlap, I would be surprised if Medtronic looked for large headcount reductions in sales and marketing and given Medtronic's strong commitment to R&D, I wouldn't think it would look to slash personnel, projects, or spending here either.

Factoring in a slightly lower tax rate (and access to its overseas cash pile), I expect Medtronic to earn a long-term rate of return in the 6% to 10% from this deal. That is below the company's trailing return on assets, equity, and invested capital, but that also reflects the realities of how difficult it is for Medtronic to find large-scale reinvestment opportunities that offer attractive expected returns.

What does this mean for others?
Johnson & Johnson cannot be thrilled to see its primary rival in surgical and energy tools acquired by a company that will maintain (if not accelerate) its commitment to R&D. Likewise, more competition in areas like peripheral care won't be welcomed by Johnson & Johnson, Boston Scientific, Bard, or Abbott. This deal may likewise prove to be disappointing to a host of small/mid-cap med-techs that could have made worthwhile additions for either Medtronic or Covidien.

All told, this may not be a good deal for the small/mid-cap space. If other companies adopt Medtronic's view that scale and scope is increasingly vital in the evolving med-tech world, larger companies may look more toward mergers of equals (or near-equals) instead of the more historically typical acquisitions of product/market-specific small companies.

This may also be a big enough tax inversion deal that it really spurs the U.S. government to tie up that loophole. If the window is closing, I could see other companies like Essilor, Coloplast, Smith & Nephew, Getinge, and bioMerieux coming into play. Japanese companies like Terumo and Olympus could also get a look, but it is relatively rare for U.S. companies to acquire Japanese companies.

The bottom line
Medtronic has done a good job of answering questions about how it would augment its growth potential and address its growing OUS cash pile. Adding Covidien brings a great business that addresses numerous large markets with growth potential from both new product introductions in developed markets and volume growth in emerging markets. Covidien also offers the potential to reduce the tax rate and achieve some significant cost reductions. 

The one downside here is on taxes. While I believe Covidien does add value to Medtronic, shareholders of both companies will incur a taxable event in this combination. Apart from that short-term pain, this is a deal with the potential to provide meaningful long-term gain to both groups of shareholders.

Leaked: A huge game-changing small-cap opportunity
This smart device –kept secret until now – could mark a new revolution in smart tech (with big implications for health care). It’s a gigantic market opportunity -- ABI Research predicts 485 million of its type will be sold per year. To learn about the small-cap stock making this device possible – the stock that could mint millionaires left and right when its full market potential is realized – click here.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers